Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína3. fázis

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D

A legfontosabb adatok

Ki végzi
Guangzhou Zhiyi Biotechnology Co., Ltd.
Hol
Binzhou és Wuxi (Kína)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
1298 fő, tervezett
Kezdés
2024. márc. 16.
Várható befejezés
2027. jan.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Live SK08 powder
  • Placebo
A regiszteradat frissítve
2025. április 3.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with irritable bowel syndrome with diarrhea (IBS-D). It compares Live SK08 powder with a dummy powder (placebo).

Életkor
18 to 70 years
Nem
All sexes
A betegség stádiuma
IBS-D by the Rome IV criteria: symptoms for at least 6 months, with belly pain at least 1 day per week in the past 3 months. During the run-in period, loose or watery stools (Bristol type 6 or 7) on at least 4 days per week, with average pain of at least 3.0. A colonoscopy within 12 months before the run-in period, with a normal result or only small findings.
Korábbi kezelés
No relief drugs or painkillers in the 14 days before randomization. No experimental drug or device in the 3 months before consent. No earlier SK08 study.

A részvétel fő kizáró okai

  • IBS with constipation, mixed or unclassified IBS
  • Other bowel or digestive diseases, lactose intolerance or celiac disease
  • Serious heart, lung or kidney disease, cancer, autoimmune or metabolic disease
  • Earlier belly or pelvic surgery, except some listed operations
  • Pregnant or breastfeeding women

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • 1.Voluntarily sign informed consent, be able to comply with the protocol and be able to carry out related procedures, including the completion of diary during the induction period and throughout the study period
  • 2. Age between 18 and 70 years old (including two-end values, based on the date of signing the Master Informed consent), regardless of gender
  • 3. IBS-D patients with clinical symptoms meeting the Rome IV definition, that is, the course of disease for at least 6 months, repeated abdominal pain in the past 3 months, an average of at least 1 day per week, combined with two or more of the following conditions: (1) Abdominal pain is related to defecation; ② Abdominal pain accompanied by changes in the frequency of defecation; ③ Abdominal pain accompanied by changes in fecal trait. When abnormal stool occurred in the last 3 months, the proportion of abnormal stool was >25% for Bristol fecal trait type 6 or 7, and <25% for Bristol fecal trait type 1 or 2 (see Appendix 13.3: IBS Rome IV diagnostic criteria and subtype classification criteria)
  • 4. Colonoscopy has been completed within 12 months before the run-in period. The ileocecal part should be observed during endoscopy, and the ileocecal flap image recording should be included in the report. They may be included if one of the following conditions is met: (i) The colonoscopy report is normal; (ii) Abnormalities reported by colonoscopy, such as hemorrhoids and intestinal polyps (diameter ≤5mm and number ≤3), were determined by the investigator to be eligible for inclusion; (iii) Colonoscopy reported that the diameter of intestinal polyps was >5mm or the number of intestinal polyps was >3; after endoscopic treatment, the diameter of residual intestinal polyps was ≤5mm and the number of intestinal polyps was ≤3, and the investigators determined that they could be included in the group
  • 5. Colonoscopy or endoscopy should be performed at least 4 weeks before the run-in period, and IBS symptoms still occur before the run-in period
  • 6. During the run-in period, the average number of days with type 6 or type 7 fecal traits per week was ≥4 days, and the average NRS score (the highest score within 24 hours) of daily abdominal pain intensity on days with type 6 or type 7 fecal traits was ≥3.0
  • 7. Patients completed diary at least 5 days in the week before randomization (D-7 to D-1) and at least 10 days in the 2 weeks before randomization (D-14 to D-1)
  • 8. The patient had not used any relief drugs or analgesics in the 14 days prior to randomization
  • 9. During the period from the signing of the master informed consent to the end of the final study visit, patients agreed to maintain their usual diet and lifestyle, such as no changes in dietary structure or exercise patterns

Ki nem vehet részt

  • 6. Previous history of abdominal and pelvic surgery, except appendectomy, caesarean section or tubal ligation without intestinal complications, hernia repair
  • 7. Patients with a previously diagnosed psychiatric disorder or moderate to severe depression or generalized anxiety disorder requiring medication (PHQ-9≥10 or GAD-7≥10 during screening)
  • 15. During the trial, drugs that affect gastrointestinal movement and function cannot be discontinued, It includes antibiotics (such as erythromycin), drugs that regulate intestinal microecology (such as bifidobacterium), parasympathetic inhibitors (such as scopolamine, atropine, belladona, etc.), muscle relaxants (such as succinylcholine), antidiarrheal agents (such as loperamide, montmorillonite powder, etc.), opioids, drugs that inhibit gastric acid secretion, etc
  • 18. Have participated in any clinical trial and used the experimental drug or device within 3 months prior to signing the informed consent
  • 19. The patient had previously participated in a clinical study of SK08
  • 2. Patients with organic gastrointestinal diseases were excluded from the following conditions: superficial gastritis, grade I erosive gastritis, chronic atrophic gastritis found by endoscopy but judged by the investigator to be eligible for admission (for example, no mucosal erosion or bleeding under endoscopy, and no abdominal distension, epigastric pain, acid reflux and other symptoms)
  • 3. Parenteral diseases of the digestive system such as tuberculous peritonitis, pancreatitis, cirrhosis, and biliary tract diseases are present, except for fatty liver disease that has not progressed to hepatitis, and gallstones that lack related symptoms
  • 4. Known to have lactose intolerance and celiac disease
  • 5. There are other systemic diseases, including serious diseases of the heart, lungs and kidneys, malignant tumors, autoimmune diseases, metabolic diseases (such as diabetes, diseases affecting thyroid function), reproductive system diseases (such as nonphysiologic ovarian cysts, endometriosis, severe dysmenorrhea requiring medical treatment), etc
  • 9. People who are positive for antibodies against hepatitis C virus (HCV), or human immunodeficiency virus (HIV), or syphilis, or hepatitis B surface antigen (HBsAg) and need antiviral therapy at the screening stage
  • 12. A history of drug or alcohol abuse
  • 14. Allergic to experimental drugs, rescue drugs and their ingredients
  • 8. Fecal examination results showed occult blood (+) and above (except for cases caused by hemorrhoids or female menstrual periods) or white blood cells (+) and above, and were judged by the investigator to be clinically significant
  • 10. Laboratory tests showed significant abnormalities, and the investigator determined that the patient's participation in the study may compromise his or her safety, including but not limited to: (i) Creatinine ≥1.5 times the upper limit of normal (ULN); (ii) AST≥2 times upper limit of normal (ULN) and/or ALT≥2 times upper limit of normal (ULN) and/or total bilirubin ≥1.5 times upper limit of normal (ULN)
  • 1. Patients with constipated, mixed and amorphous IBS
  • 13. Even with the help of liquids, patients are unable to take oral solid dosage forms
  • 16. A woman who is pregnant or breastfeeding
  • 17. At the time of the trial, both the patient and his partner were unable or unwilling to use reliable contraception to prevent pregnancy, or the female or male patient's partner had a recent pregnancy plan
  • 20.According to the judgment of the investigator, the participants are not suitable to participate in this clinical trial

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 70 év között vagy?

Helyszínek itt: Kína

  • Binzhou Medical University HospitalBinzhou, KínaContact: Ning Shi, MasterRésztvevőt keres
  • Wuxi People's HospitalWuxi, KínaContact: Yuhua Xu, BachelorRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the efficacy and safety of Live SK08 Powder compared with placebo in the treatment of participants with irritable bowel syndrome with diarrhea.

A vizsgálat 2 csoportja

  • Live SK08 powderA vizsgált kezelés

    Live SK08 powder, (1-25)×10\^9 CFU, oral, twice daily for up to 52 weeks period.

  • PlaceboPlacebo, összehasonlításként

    SK08 placebo matching powder, oral, twice daily for up to 52 weeks period.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06247046: ki vehet részt
A regiszteradat frissítve
2025. április 3.